國立虎尾科技大學 |

Studies of the Norovirus Protease as a Target for Antiviral Therapeutics.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Studies of the Norovirus Protease as a Target for Antiviral Therapeutics./
作者:	Nana, Vanessa Kamdoum.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2020,
面頁冊數:	69 p.
附註:	Source: Masters Abstracts International, Volume: 82-04.
Contained By:	Masters Abstracts International82-04.
標題:	Biochemistry. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28029118
ISBN:	9798678141408

Studies of the Norovirus Protease as a Target for Antiviral Therapeutics.
Nana, Vanessa Kamdoum.

Studies of the Norovirus Protease as a Target for Antiviral Therapeutics. - Ann Arbor : ProQuest Dissertations & Theses, 2020 - 69 p.

Source: Masters Abstracts International, Volume: 82-04.

Thesis (M.Sc.)--Wayne State University, 2020.

This item must not be sold to any third party vendors.

Human norovirus is the leading cause of acute gastroenteritis worldwide, affecting every year over 600 million people. Children under the age of five are more at risk with elderly and immune-compromised individuals. Death associated with the disease is reported at approximately 200,000 every year and children account for the vast majority. Human norovirus also entails severe economic losses, with an estimated cost of 60 billion dollars per year. Despite the societal and economic burden associated to this disease, currently there are no vaccines or antiviral therapeutics to prevent or treat this infection. The Norovirus protease (NoV 3CLpro) represents a promising target for the discovery of antiviral agents for the pivotal role it plays in the replicative life of the virus. Starting with two designed peptidomimetic compounds respectively RS-3150 and RS-2905 identified as potent inhibitors against the NoV 3CLpro. A series of thermal shift assays were conducted to study the stability effect of these small molecules on the NoV 3CLpro and validate them for further structural studies. A FRET-based enzyme assay screen was carried out and a ligand-based pharmacophore model was developed with the aim to identify novel, improved, and effective small molecules against the norovirus protease. With 3 to 6° shift difference compound RS-3150 confers a better stability to the NoV 3CLpro than RS-2905, and has been validated by thermal shift assay and compound titration studies as an excellent candidate for future co-crystallography studies with the NoV 3CLpro. The in silico pharmacophore based approach identified a new small molecule inhibitor with similar binding affinity as RS-3150 and better predicted pharmacological properties. Further optimization of this molecule along with the other top hits could represent the groundwork of a new class of inhibitors of the Norovirus protease.

ISBN: 9798678141408Subjects--Topical Terms:

582831
Biochemistry.
Subjects--Index Terms:

3CLike pro

Studies of the Norovirus Protease as a Target for Antiviral Therapeutics.
LDR:02966nam a2200349 4500 001 1038008
005 20210910100653.5
008 211029s2020 ||||||||||||||||| ||eng d
020 $a 9798678141408
035 $a (MiAaPQ)AAI28029118
035 $a AAI28029118
040 $a MiAaPQ $c MiAaPQ
100 1 $a Nana, Vanessa Kamdoum. $3 1335331
245 1 0 $a Studies of the Norovirus Protease as a Target for Antiviral Therapeutics.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2020
300 $a 69 p.
500 $a Source: Masters Abstracts International, Volume: 82-04.
500 $a Advisor: Kovari, Ladislau.
502 $a Thesis (M.Sc.)--Wayne State University, 2020.
506 $a This item must not be sold to any third party vendors.
520 $a Human norovirus is the leading cause of acute gastroenteritis worldwide, affecting every year over 600 million people. Children under the age of five are more at risk with elderly and immune-compromised individuals. Death associated with the disease is reported at approximately 200,000 every year and children account for the vast majority. Human norovirus also entails severe economic losses, with an estimated cost of 60 billion dollars per year. Despite the societal and economic burden associated to this disease, currently there are no vaccines or antiviral therapeutics to prevent or treat this infection. The Norovirus protease (NoV 3CLpro) represents a promising target for the discovery of antiviral agents for the pivotal role it plays in the replicative life of the virus. Starting with two designed peptidomimetic compounds respectively RS-3150 and RS-2905 identified as potent inhibitors against the NoV 3CLpro. A series of thermal shift assays were conducted to study the stability effect of these small molecules on the NoV 3CLpro and validate them for further structural studies. A FRET-based enzyme assay screen was carried out and a ligand-based pharmacophore model was developed with the aim to identify novel, improved, and effective small molecules against the norovirus protease. With 3 to 6° shift difference compound RS-3150 confers a better stability to the NoV 3CLpro than RS-2905, and has been validated by thermal shift assay and compound titration studies as an excellent candidate for future co-crystallography studies with the NoV 3CLpro. The in silico pharmacophore based approach identified a new small molecule inhibitor with similar binding affinity as RS-3150 and better predicted pharmacological properties. Further optimization of this molecule along with the other top hits could represent the groundwork of a new class of inhibitors of the Norovirus protease.
590 $a School code: 0254.
650 4 $a Biochemistry. $3 582831
650 4 $a Molecular biology. $3 583443
653 $a 3CLike pro
653 $a Antiviral
653 $a Drug discovery
653 $a Human norovirus
690 $a 0487
690 $a 0307
710 2 $a Wayne State University. $b Biochemistry and Molecular Biology. $3 1335332
773 0 $t Masters Abstracts International $g 82-04.
790 $a 0254
791 $a M.Sc.
792 $a 2020
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28029118